A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura

Blood

Volumn 118, Issue 7, 2011, Pages 1746-1753

  Scully, Marie ^a   McDonald, Vickie ^b   Cavenagh, Jamie ^c   Hunt, Beverley J ^d   Longair, Ian ^a   Cohen, Hannah ^a   Machin, Samuel J ^d  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB; STEROID; TROPONIN T;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACTERIAL INFECTION; BLOOD PRESSURE; BRAIN INFARCTION; CELLULITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; HAIR LOSS; HEADACHE; HEART DISEASE; HELLP SYNDROME; HUMAN; HYPOTENSION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUTROPHIL COUNT; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PLASMAPHERESIS; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; RELAPSE; SIDE EFFECT; SKIN INFECTION; SPONTANEOUS ABORTION; STILLBIRTH; THORAX PAIN; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VASCULAR DISEASE; VIRUS INFECTION;

EID: 80051866867     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-341131     Document Type: Article

References (31)

1. Scully M., Brown J., Patel R., McDonald V., Brown C.J., Machin S. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: Evidence for an immunogenetic link. J Thromb Haemost. 2010;8(2):257-262.
2. Allford S.L., Hunt B.J., Rose P., Machin S.J. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol. 2003;120(4):556-573.
3. Coppo P., Wolf M., Veyradier A., et al. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol. 2006;132(1):66-74. (Pubitemid 43381572)
4. Tuncer H.H., Oster R.A., Huang S.T., Marques M.B. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpurahemolytic uremic syndrome: A single-institution experience. Transfusion. 2007;47(1):107-114. (Pubitemid 46006317)
5. Vesely S.K., George J.N., Lammle B., et al.ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102(1):60-68. (Pubitemid 36759636)
6. Heidel F., Lipka D.B., Von Auer C., Huber C., Scharrer I., Hess G. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia. Thromb Haemost. 2007;97(2):228-233. (Pubitemid 46592142)
7. Reddy P.S., Deauna-Limayo D., Cook J.D., et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol. 2005; 84(4):232-235. (Pubitemid 40425069)
8. Scully M., Cohen H., Cavenagh J., et al. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451-461. (Pubitemid 46046304)
9. George J.N. How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood. 2010; 116(20):4060-4069.
10. Gerritsen H.E., Turecek P.L., Schwarz H.P., Lammle B., Furlan M. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost. 1999;82(5):1386-1389. (Pubitemid 29527624)
11. Yarranton H., Lawrie A.S., Purdy G., MacKie I.J., Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med. 2004;14(1):39-44. (Pubitemid 38477758)
12. Scheiflinger F., Knobl P., Trattner B., et al. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102(9):3241-3243. (Pubitemid 37314762)
13. Keren DF, McCoy J, Carey J, eds. Flow Cytometry in Clinical Diagnosis. Chicago, IL:ASCP Press; 2006.
14. Scully M., Yarranton H., Liesner R., et al. Regional UK TTP registry: Correlation with laboratoryADAMTS13 analysis and clinical features. Br J Haematol. 2008;142(5):819-826.
15. Rock G.A., Shumak K.H., Buskard N.A., et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991;325(6):393-397.
16. Böhm M., Betz C., Miesbach W., et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol. 2005;129(5):644-652. (Pubitemid 40825826)
17. Kappers-Klunne M.C., Wijermans P., Fijnheer R., et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130(5):768-776. (Pubitemid 43906650)
18. Cataland S.R., Jin M., Lin S., et al. Cyclosporin and plasma exchange in thrombotic thrombocytopenic purpura: Long-term follow-up with serial analysis of ADAMTS13 activity. Br J Haematol. 2007;139(3):486-493. (Pubitemid 47512185)
19. Cataland S.R., Jin M., Ferketich A.K., et al. An evaluation of cyclosporin and corticosteroids individually as adjuncts to plasma exchange in the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2007;136(1):146-149. (Pubitemid 44912601)
20. Bresin E., Gastoldi S., Daina E., et al. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost. 2009;101(2):233-238.
21. Fakhouri F., Vernant J.P., Veyradier A., et al. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: A study of 11 cases. Blood. 2005;106(6):1932-1937. (Pubitemid 41291703)
22. Jasti S., Coyle T., Gentile T., Rosales L., Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: A report of 12 cases and review of literature. J Clin Apher. 2008;23(5):151-156.
23. Zhan H., Streiff M.B., King K.E., Segal J.B. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: Clinical outcomes and risk factors for relapse. Transfusion. 2010;50(4):868-874.
24. Cataland S.R., Yang S.B., Witkoff L., et al. Demographic and ADAMTS13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol. 2009;83(6):559-564.
25. Coppo P., Bengoufa D., Veyradier A., et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004;83(4):233-244. (Pubitemid 38955446)
26. Bandarenko N., Brecher M.E. United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. J Clin Apher. 1998;13(3):133-141. (Pubitemid 28507005)
27. Nguyen L., Li X., Duvall D., Terrell D.R., Vesely S.K., George J.N. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: The experience of the Oklahoma Registry, 1989 through 2006. Transfusion. 2008;48(2):349-357.
28. Shumak K.H., Rock G.A., Nair R.C. Late relapses in patients successfully treated for thrombotic thrombocytopenic purpura. Canadian Apheresis Group. Ann Intern Med. 1995;122(8):569-572.
29. Willis M.S., Bandarenko N. Relapse of thrombotic thrombocytopenic purpura: Is it a continuum of disease? Semin Thromb Hemost. 2005;31(6):700-708. (Pubitemid 43063088)
30. Hovinga J.A., Vesely S.K., Terrell D.R., Lammle B., George J.N. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511.
31. McDonald V., Manns K., MacKie I.J., Machin S.J., Scully M.A. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201-1208.